{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:41Z","timestamp":1790960561775,"version":"4.1.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Non-alcoholic fatty liver disease (NAFLD) incidence has been rapidly increasing, and it has emerged as one of the major diseases of the modern world. NAFLD constitutes a simple fatty liver to chronic non-alcoholic steatohepatitis (NASH), which often leads to liver fibrosis or cirrhosis, a serious health condition with limited treatment options. Many a time, NAFLD progresses to fatal hepatocellular carcinoma (HCC). Nuclear receptors (NRs), such as liver X receptor-\u03b1 (LXR-\u03b1) and closely associated farnesoid X receptor (FXR), are ligand-inducible transcription factors that regulate various metabolism-associated gene expressions and repression and play a major role in controlling the pathophysiology of the human liver. Withaferin A is a multifaceted and potent natural dietary compound with huge beneficial properties and plays a vital role as an anti-inflammatory molecule.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold><jats:italic>In vivo<\/jats:italic>: Swill albino mice were fed with western diet and sugar water (WDSW) for 12, 16, and 20\u00a0weeks with suitable controls. Post necropsy, liver enzymes (AST, ALT, and ALP) and lipid profile were measured by commercially available kits using a semi-auto analyzer in serum samples. Liver histology was assessed using H&amp;amp;E and MTS stains to check the inflammation and fibrosis, respectively, using paraffin-embedded sections and mRNA expressions of these markers were measured using qRT-PCR method. TGF-\u03b21 levels in serum samples were quantified by ELISA. <jats:italic>In vitro<\/jats:italic>: Steatosis was induced in HepG2 and Huh7 cells using free fatty acids [Sodium Palmitate (SP) and Oleate (OA)]. After induction, the cells were treated with Withaferin A in dose-dependent manner (1, 2.5, and 5 \u03bcM, respectively). <jats:italic>In vitro<\/jats:italic> steatosis was confirmed by Oil-Red-O staining. Molecular Docking: Studies were conducted using Auto Dock Vina software to check the binding affinity of Withaferin-A to LXR-\u03b1 and FXR.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We explored the dual receptor-activating nature of Withaferin A using docking studies, which potently improves high-fat diet-induced NAFLD in mice and suppresses diet-induced hepatic inflammation and liver fibrosis <jats:italic>via<\/jats:italic> LXR\/FXR. Our <jats:italic>in vitro<\/jats:italic> studies also indicated that Withaferin A inhibits lipid droplet accumulation in sodium palmitate and oleate-treated HepG2 and Huh7 cells, which may occur through LXR-\u03b1 and FXR-mediated signaling pathways. Withaferin A is a known inhibitor of NF-\u03baB-mediated inflammation. Intriguingly, both LXR-\u03b1 and FXR activation inhibits inflammation and fibrosis by negatively regulating NF-\u03baB. Additionally, Withaferin A treatment significantly inhibited TGF-\u03b2-induced gene expression, which contributes to reduced hepatic fibrosis.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> Thus, the LXR\/ FXR dual receptor activator Withaferin A improves both NAFLD-associated liver inflammation and fibrosis in mouse models and under <jats:italic>in vitro<\/jats:italic> conditions, which makes Withaferin A a possibly potent pharmacological and therapeutic agent for the treatment of diet-induced NAFLD.<\/jats:p>","DOI":"10.3389\/fphar.2023.1135952","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:08:28Z","timestamp":1677132508000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR\/FXR dual receptor activator"],"prefix":"10.3389","volume":"14","author":[{"given":"Varsha D.","family":"Shiragannavar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmala G.","family":"Sannappa Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshana D.","family":"Puttahanumantharayappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas H.","family":"Karunakara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashanka K.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya P.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna K.","family":"Santhekadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40360-021-00524-8","article-title":"Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis","volume":"22","author":"Akbari","year":"2021","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3978\/j.issn.2305-5839.2014.12.06","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12325-016-0306-9","article-title":"The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans","volume":"33","author":"Ballestri","year":"2016","journal-title":"Adv. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1053\/j.gastro.2010.11.053","article-title":"Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease","volume":"140","author":"Beaven","year":"2011","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/annrheumdis-2013-204401","article-title":"Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/biomedicines9121776","article-title":"Exploring the gamut of receptor tyrosine kinases for their promise in the management of non-alcoholic fatty liver disease","volume":"9","author":"Bhave","year":"2021","journal-title":"Biomedicines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: A patient guideline","volume":"3","author":"Busetto","year":"2021","journal-title":"JHEP Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"Nafld: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11010-011-1211-9","article-title":"Saturated fatty acid induction of endoplasmic reticulum stress and apoptosis in human liver cells via the PERK\/ATF4\/CHOP signaling pathway","volume":"364","author":"Cao","year":"2012","journal-title":"Mol. Cell Biochem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.11648\/j.ijg.20190301.12","article-title":"Characterization of EDP\u2010305, a highly potent and selective farnesoid X receptor agonist, for the treatment of non\u2010alcoholic steatohepatitis","volume":"3","author":"Chau","year":"2019","journal-title":"Int. J. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1007\/s11606-019-05340-9","article-title":"Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample: The CARDIA study","volume":"34","author":"Cleveland","year":"2019","journal-title":"J. Gen. Intern Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/toxsci\/kfp094","article-title":"Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice","volume":"110","author":"Cui","year":"2009","journal-title":"Toxicol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"751859","DOI":"10.1155\/2014\/751859","article-title":"Coordinated actions of FXR and LXR in metabolism: From pathogenesis to pharmacological targets for type 2 diabetes","volume":"2014","author":"Ding","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.3892\/ijmm.2019.4136","article-title":"Activation of FXR by Obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR","volume":"43","author":"Dong","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jcmgh.2021.12.018","article-title":"Hepatic reduction in cholesterol 25-hydroxylase aggravates diet-induced steatosis","volume":"13","author":"Dong","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: New docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"B20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/hep.21802","article-title":"Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis","volume":"46","author":"Elsharkawy","year":"2007","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.3390\/ijms20205045","article-title":"Liver X receptors regulate cholesterol metabolism and immunity in hepatic nonparenchymal cells","volume":"20","author":"Endo-Umeda","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1074\/jbc.M307363200","article-title":"Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis","volume":"279","author":"Figge","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1208\/s12248-013-9473-7","article-title":"Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice","volume":"15","author":"Gao","year":"2013","journal-title":"AAPS J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1208\/s12248-012-9429-3","article-title":"The liver X receptor agonist T0901317 protects mice from high fat diet-induced obesity and insulin resistance","volume":"15","author":"Gao","year":"2013","journal-title":"AAPS J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymgme.2004.07.007","article-title":"T0901317 is a dual LXR\/FXR agonist","volume":"83","author":"Houck","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1073\/pnas.0830671100","article-title":"Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue","volume":"100","author":"Laffitte","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nm.4145","article-title":"Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/antiox11061131","article-title":"NADPH oxidases connecting fatty liver disease, insulin resistance and type 2 diabetes: Current knowledge and therapeutic outlook","volume":"11","author":"Nasc\u00e8","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3389\/fimmu.2019.02893","article-title":"Macrophage function in the pathogenesis of non-alcoholic fatty liver disease: The Mac Attack","volume":"10","author":"Oates","year":"2019","journal-title":"Front. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/00498254.2021.1900626","article-title":"FXR activation prevents liver injury induced by Tripterygium wilfordii preparations","volume":"51","author":"Peng","year":"2021","journal-title":"Xenobiotica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"bpab023","DOI":"10.1093\/biomethods\/bpab023","article-title":"Preparation of fatty acid solutions exerts significant impact on experimental outcomes in cell culture models of lipotoxicity","volume":"7","author":"R\u00f6mer","year":"2021","journal-title":"Biol. Methods Protoc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010715-103209","article-title":"Nuclear receptors as therapeutic targets in liver disease: Are we there yet?","volume":"56","author":"Rudraiah","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.fob.2014.03.012","article-title":"Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGF\u03b2 signaling","volume":"4","author":"Santhekadur","year":"2014","journal-title":"FEBS Open Bio"},{"key":"B36","doi-asserted-by":"publisher","first-page":"13952","DOI":"10.1074\/jbc.m111.321646","article-title":"Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor \u03baB and miR-221","volume":"287","author":"Santhekadur","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.biopha.2017.04.002","article-title":"Is Withaferin A, a magic bullet for metabolic syndrome?","volume":"92","author":"Santhekadur","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/biof.1546","article-title":"Withaferin A reverses bile duct ligation-induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2\/Snail1, vimentin, and NF\u03baB signaling","volume":"45","author":"Sayed","year":"2019","journal-title":"Biofactors"},{"key":"B39","doi-asserted-by":"publisher","first-page":"628506","DOI":"10.3389\/fonc.2020.628506","article-title":"Withaferin A acts as a novel regulator of liver X receptor-\u03b1 in HCC","volume":"10","author":"Shiragannavar","year":"2021","journal-title":"Front. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"100127","DOI":"10.1016\/j.medidd.2022.100127","article-title":"Discovery of eukaryotic cellular receptor for Withaferin A, a multifaceted drug from Withania somnifera plant","volume":"14","author":"Shiragannavar","year":"2022","journal-title":"Med. Drug Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3748\/wjg.v21.i13.3777","article-title":"Current pharmacological therapies for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"21","author":"Takahashi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3724\/abbs.2022030","article-title":"Ch25h and 25-HC prevent liver steatosis through regulation of cholesterol metabolism and inflammation","volume":"54","author":"Wang","year":"2022","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/cvr\/cvp180","article-title":"Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling","volume":"84","author":"Wu","year":"2009","journal-title":"Cardiovasc Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"609900","DOI":"10.3389\/fimmu.2020.609900","article-title":"Predicting non-alcoholic fatty liver disease progression and immune deregulations by specific gene expression patterns","volume":"11","author":"Zeng","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1135952\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:08:35Z","timestamp":1677132515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1135952\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":49,"alternative-id":["10.3389\/fphar.2023.1135952"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1135952","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"1135952"}}